Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment

Phase 4

Terminated

Conditions: Multiple Sclerosis
Cognitive Impairment

Interventions: Drug: Rivastigmine transdermal patch
Drug: Placebo

First Posted Date: 2009-04-15

Last Posted Date: 2012-03-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 86

Registration Number: NCT00881205

Locations: 🇩🇪
Novartis Investigational Site, Hamburg, Germany
🇩🇪
Novartis Investigative Site, Wolfratshausen, Germany
🇩🇪
Novartis Investigative SIte, Berlin, Germany

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Basal Cell Carcinoma
Advanced Solid Tumor Cancers
Medulloblastoma

Interventions: Drug: LDE225

First Posted Date: 2009-04-13

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT00880308

Locations: 🇺🇸
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5), San Antonio, Texas, United States
🇬🇧
Novartis Investigative Site, Leicester, United Kingdom
🇺🇸
University of Pittsburgh Medical Center SC, Pittsburgh, Pennsylvania, United States

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

Phase 2

Completed

Conditions: Refractory Leukemia
Acute Myelogenous Leukemia

Interventions: Drug: Panobinostat/LBH589

First Posted Date: 2009-04-13

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT00880269

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom
🇺🇸
Memorial Sloan Kettering Cancer Center Dept. of MSKCC (2), NY, New York, United States
🇺🇸
University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States

and more 5 locations

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Malignancies

Interventions: Drug: HSP990

First Posted Date: 2009-04-13

Last Posted Date: 2020-12-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00879905

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Cataluña, Spain

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

Phase 2

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: BAF312
Drug: Placebo

First Posted Date: 2009-04-10

Last Posted Date: 2020-01-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 297

Registration Number: NCT00879658

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

Phase 3

Completed

Conditions: Advanced Gastric Cancer

Interventions: Drug: Everolimus placebo
Drug: Everolimus
Drug: Best Supportive Care (BSC)

First Posted Date: 2009-04-10

Last Posted Date: 2015-11-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 656

Registration Number: NCT00879333

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
🇺🇸
Henry Ford Hospital Dept. of Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
University of Washington Cancer Care Seattle Cancer Alliance, Seattle, Washington, United States

and more 6 locations

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Phase 2

Completed

Conditions: Beta Thalassemia Transfusion Dependent

Interventions: Drug: Deferasirox

First Posted Date: 2009-04-09

Last Posted Date: 2016-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT00879242

Locations: 🇮🇹
Novartis Investigative Site, Orbassano, Italy

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Phase 2

Completed

Conditions: Herpes Labialis

Interventions: Drug: Famciclovir

First Posted Date: 2009-04-08

Last Posted Date: 2021-06-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT00878072

Locations: 🇺🇸
Westover Heights Clinic, Portland, Oregon, United States
🇺🇸
Women's Health Care at Frost Street, San Diego, California, United States
🇺🇸
Medisphere Medical Research Center, LLC, Evansville, Indiana, United States

and more 9 locations

Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis B

Phase 4

Completed

Conditions: Compensated Chronic Hepatitis B

Interventions: Drug: telbivudine/LDT600

First Posted Date: 2009-04-07

Last Posted Date: 2012-05-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT00877149

Locations: 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳
Peking University People's Hospital, Peking, China
🇨🇳
First Hospital of Peking University, Peking, China

and more 1 locations

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Salmeterol 50 µg
Drug: Indacaterol 300 µg

First Posted Date: 2009-04-07

Last Posted Date: 2011-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 186

Registration Number: NCT00876694

Locations: 🇯🇵
Novartis Investigator site, Sapporo, Japan
🇯🇵
Novartis Investigator Site, Yokohama, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy